Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
  • ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII
    Publication number: 20200277402
    Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 3, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
  • Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
    Patent number: 10759870
    Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 1, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
  • ANTIBODY HAVING ENHANCED ACTIVITY, AND METHOD FOR MODIFYING SAME
    Publication number: 20200270363
    Abstract: As a result of producing ACE910 variants in which various sites of the constant regions were modified, the inventors discovered bispecific antibodies having FVIII mimetic activity higher than that of ACE910. The inventors also identified mutation positions that elevate the FVIII mimetic activity and discovered methods for elevating the FVIII mimetic activity by using the mutations.
    Type: Application
    Filed: December 22, 2016
    Publication date: August 27, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Yuri Teranishi
  • Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate
    Patent number: 10744201
    Abstract: A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 18, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Osamu Okuda, Noriaki Yoshida, Ravinder Nath Maini
  • Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
    Patent number: 10738111
    Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: August 11, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
  • RET INHIBITOR
    Publication number: 20200246349
    Abstract: A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can he used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tatsushi KODAMA, Hiroshi SAKAMOTO, Toshiyuki TSUKAGUCHI
  • ANTIBODY MOLECULES
    Publication number: 20200231688
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 23, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Method for identifying epitope on protein
    Patent number: 10718781
    Abstract: In one aspect, the present invention provides, for example, an improved method for identifying an epitope on a protein, comprising the following steps: (A) contacting a major histocompatibility complex (MHC molecule)-expressing cell differentiated from a stem cell or a progenitor cell derived therefrom with a target protein; (B) isolating a complex of a peptide contained in the target protein and the MHC molecule from the MHC molecule-expressing cell; and (C) eluting the peptide from the complex and identifying the peptide.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: July 21, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoaki Inoue, Shunsuke Ito, Nobuo Sekiguchi
  • MULTISPECIFIC ANTIGEN-BINDING MOLECULES HAVING BLOOD COAGULATION FACTOR VIII (FVIII) COFACTOR FUNCTION-SUBSTITUTING ACTIVITY AND PHARMACEUTICAL FORMULATIONS CONTAINING SUCH A MOLECULE AS AN ACTIVE INGREDIENT
    Publication number: 20200223940
    Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 16, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
  • POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
    Publication number: 20200207805
    Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
  • Method for determining application of therapy to multiple sclerosis (MS) patient
    Patent number: 10697883
    Abstract: According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: June 30, 2020
    Assignees: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takashi Yamamura, Masakazu Nakamura
  • Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
    Patent number: 10696743
    Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 30, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
  • METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE
    Publication number: 20200199241
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • AntiPlexin A1 agonist antibody
    Patent number: 10688178
    Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 23, 2020
    Assignees: Osaka University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
  • FGFR3 fusion gene and pharmaceutical drug targeting same
    Patent number: 10689705
    Abstract: The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 23, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshito Nakanishi, Nukinori Akiyama, Yukari Nishito
  • ANTIBODY AGAINST SECRETED N-TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3
    Publication number: 20200181248
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 11, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki ABURATANI, Yutaka MIDORIKAWA, Kiyotaka NAKANO, Iwao OHIZUMI, Yukio ITO, Susumu TOKITA
  • MODIFIED Fc REGION OF ANTIBODY
    Publication number: 20200181257
    Abstract: Polypeptides with improved stability as compared to that of a parent polypeptide were successfully obtained by modifying at least one amino acid in a loop region of the antibody Fc region. Furthermore, by combining multiple amino acid modifications in the loop region, polypeptides with maintained or enhanced Fc?R-binding activity as well as improved thermal stability, polypeptides with decreased Fc?R-binding activity as well as improved thermal stability, and polypeptides with not only improved thermal stability and adjusted Fc?R-binding activity but also decreased aggregate content, as compared to those of a parent polypeptide, were successfully obtained.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 11, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Taichi Kuramochi, Meiri Kawazoe, Futa Mimoto, Atsuhiko Maeda, Tomoyuki Igawa
  • METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
    Publication number: 20200181669
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • ANTIBODIES COMPRISING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY CHANGES ACCORDING TO THE ION CONCENTRATION CONDITION, Fc REGION VARIANTS, OR IL-8-BINDING ANTIBODIES
    Publication number: 20200172610
    Abstract: One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 4, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Yuji Hori, Genki Nakamura, Masaru Muraoka
  • METHOD FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION
    Publication number: 20200172569
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda